95 results about "Infection drug" patented technology

The invention belongs to the field of gene engineering and discloses a target sequence recognized by a CRISPR (clustered regularly interspaced short palindromic repeat)-Cas9 (CRISPR-associated protein 9) system stemming from streptococcus thermophilus. The target sequence is shown as the n-20th position of any one of SEQ ID NO: 1-88, wherein n ranges from 1 to 5. The invention further discloses sgRNA (single guide ribonucleic acid) with a sequence being 5'-recognition sequence-recruitment Cas9 sequence-3' and a coding DNA (deoxyribonucleic acid) molecule thereof, and a DNA sequence corresponding to the recognition sequence is as same as the target sequence. The invention further discloses the CRISPR-Cas9 system comprising Cas9 and the sgRNA and/or Cas9-carried coding sequence and an sgRNA coding sequence vector. The invention further discloses application of the CRISPR-Cas9 system to CCR5 gene editing and HIV (human immunodeficiency virus) infection drug preparation. CCR5 gene editing can be achieved to protect cells from HIV infection.

The invention provides a construction method of a kidney transplantation anti-infection drug dosage prediction model. The method comprises the following steps: establishing a group pharmacokinetic model of an anti-infective drug by adopting a nonlinear mixed effect model, a two-atrioventricular model and a mixed residual model through plasma concentration analysis, and calculating pharmacokinetic parameters of the corresponding model; and carrying out related hypothesis testing and estimation on the obtained model pharmacokinetic parameters based on a bootstrap method, visual prediction testing and normalized prediction distribution errors, and completing the steps of stability and prediction capability evaluation and the like. According to the established pharmacokinetic model of the kidney transplantation patient population, the reasonable judgment on the medication scheme information is accurately realized, the reference of the optimal dosage is expected to be provided in the infection prevention and treatment process, the adverse reaction risk is reduced, the curative effect is improved, and finally the individualized administration of the anti-infection medicine of the kidney transplantation patient is realized.

The invention relates to an in-situ rapid detection method for a cell biological process. After absorption, conversion, metabolism or storage for deuterium-containing matters based on active cells, in-situ marking for deuterium in cells can be realized in different stages of the cell biological process, the cells are detected through a Raman spectrum, whether deuterium exists in the cells is identified, and then the biochemical process, cell character or function related information about the cells is obtained. The method can be used for biological and medical fields such as bacterial infection drug susceptibility testing, environmental microbial metabolism and human body cell detection. Compared with the prior art, the method has the potential of detecting the activity and metabolism of the cells for most important biomolecules, and more complex deuteration matters are allowed to be researched and used, including natural products, medicines and a deuterization mixture containing various chemical matters. The method is extremely valuable for function research of the cells under natural conditions of single cell level.

The invention discloses a polydopamine-coated Prussian blue and silver-loaded nano-composite material, and a preparation method and an application thereof. The composite material is formed by coatingPrussian blue with polydopamine and then growing nano-silver on the polydopamine in situ, and the particle size of the composite material is 100-150 nm. The preparation method comprises the followingsteps: reacting potassium ferricyanide with polyvinylpyrrolidone to obtain Prussian blue, adding dopamine into a Tris-HCl solution of Prussian blue to prepare polydopamine-coated Prussian blue, and mixing and stirring the obtained polydopamine-coated Prussian blue dispersion, ammonia water, a reducing agent and a silver nitrate solution to react in order to make nano-silver grows on the coating layer polydopamine in situ in order to obtain the product. The nano-composite material has a good antibacterial effect, is not prone to causing drug resistance of bacteria, has good stability and dispersity, the preparation method has the advantages is simple and mild, short in time consumption, low in energy consumption and easy to realize large-scale production, and the nano-composite material canbe used for preparing photo-thermal antibacterial drugs or chronic traumatic infection treatment drugs.

The invention discloses an application of p-hydroxybenzoic acid and analogue in the skin virus infection drug, which is characterized by the following: fitting for infectious drug of people breast tumour virus and herpetoviridae virus; allocating each auxiliary material to prepare different agent or personal nursing product.

The use of levo-ornidazole in the preparation of anti-parasitic infection drug is provided. It is demonstrated that levo-ornidazole is superior to dextro-ornidazole and racemic ornidazole in the therapeutic action against parasitization (especially trichomonas vaginalis infection and cecal amoeba infection), and thus it is more practicable to formulate L-ornidazole as anti-parasitic infection drugs, and particularly as drug preparations which are suitable for clinical uses, including oral preparation, intravenous preparation and vaginal preparation.

The invention discloses a spina gleditsiae extract hydrogel patch and a preparation method thereof, and belongs to the technical field of pharmaceutic preparation. The spina gleditsiae extract hydrogel patch is formed by mixing a spina gleditsiae extract and a blank hydrogel substrate; the phenolic acid compound contend of the spina gleditsiae extract is 6-7 mg/ml; the blank hydrogel substrate is formed by stirring and mixing an oil phase and a water pahse, wherein the weight ratio of the oil phase and the water phase is 50-60:100; the components of the oil phase are glycerin, polyacrylic acid, dihydroxyaluminum aminoucetate, and azone; the components of the water phase are water, carboxymethylcellulose sodium, tartaric acid, EDTA-2Na, and titanium dioxide. The spina gleditsiae extract hydrogel patch of the invention has simple substrate prescription, high water content, and strong affinity, is reliable and stable, has no irritation to skin, has good anti-infection drug effect activity, allows convenient addition of various Chinese herbal medicine extracts, and is widely applicable to aspects such as surgical wounds, general wounds, skin infection, cosmetology and skin beautification, and the like.

The invention relates to application of oxidized resveratrol and combined oxidized resveratrol and antibiotic in the preparation of an anti-fungal-infection product, belonging to the technical field of medicines. Oxidized resveratrol contains nautical components, is good in safety and has good antibacterial capacity to trichophyton rubrum and Candida albicans. When the oxidized resveratrol and an antibiotic, namely econazole nitrate jointly act on the two bacteria, the antibacterial effects on the two bacteria are superior to the antibacterial effects of dependent independent oxidized resveratrol and antibiotic on the two bacteria under the same use concentration, so that natural oxidized resveratrol is used for replacing partial econazole nitrate so as to inhibit fungi, the use amount of econazole nitrate can be reduced, and the research and development of novel, efficient and natural anti-fungal-infection drugs are benefited.

The invention provides a composite biological patch as well as a preparation method and an application thereof, and relates to the technical field of medical treatment. The composite biological patch provided by the invention comprises a hydrophobic porous layer, a compact layer and a porous scaffold, the hydrophobic porous layer is opposite to one side of a to-be-repaired tissue and is loaded with an anti-infection drug, the hydrophobicity of the hydrophobic porous layer and the loaded drug can be matched with each other, the drug can be slowly released, and the effects of prevention, anti-infection and anti-adhesion are achieved; the porous scaffold has a porous structure, faces one side of a to-be-repaired tissue, is beneficial to adhesion and growth of cells, and induces membrane tissue regeneration; the hydrophobic porous layer and the porous scaffold spacing compact layer can ensure the dimensional stability and mechanical strength of the product, and also can play a role of a barrier. The composite biological patch provided by the invention can be used for meninx repair, spinal meninx repair, rotator cuff repair, hernia repair, ophthalmology repair, breast repair, hemostasis repair or oral cavity repair.

The invention relates to a preparation method and application of effective components of polygonum capitatum, and belongs to the field of extraction of effective components of traditional Chinese medicines. The preparation method comprises the following steps: a, taking polygonum capitatum medicinal raw material, adding water for extraction, so as to obtain water extracting solution; b, processing the water extracting solution by using a macroporous adsorption resin chromatographic column; c, firstly eluting the sampled macroporous adsorption resin chromatographic column by using water, then eluting by using 70-95wt% ethanol, and collecting eluent I; d, processing the eluent I by a polyamide chromatographic column; e, recovering effluent liquid from the sampled polyamide chromatographic column, eluting by using 40-95wt% ethanol, collecting eluent II; f, mixing the effluent liquid and the eluent II, recovering ethanol, concentrating and drying to finally obtain the effective components of polygonum capitatum. The preparation method has the beneficial effect that the effective components of the polygonum capitatum, which has strong antibacterial effect and can be used for preparing anti-infection drugs can be prepared by reasonable extracting and separating methods.

The invention relates to the structure and application of an antisense oligonucleotide drug. Specifically, the structure of antisense oligonucleotides targeting casein kinase 2, alpha propeptide, and anti-enterovirus type 71, Japanese encephalitis virus and influenza virus was found, and these antisense oligonucleotides were found in Use in the preparation of medicines for treating EV71, Japanese encephalitis virus and influenza virus infection and related diseases.

The use of levo-ornidazole in the preparation of medicine for preventing and treating the anti-anaerobic bacteria infection is provided. It is demonstrated that levo-ornidazole exhibits lower toxicity and less central inhibition effects than dextro-ornidazole or racemic ornidazole. L-ornidazole possesses pharmacokinetics characteristics, which are superior to that of the racemic ornidazole, and anti-anaerobic activities which are slightly better than or substantially the same as that of the racemic ornidazole. Also, this invention particularly relates to a preparation process, which comprises formulating L-ornidazole as anti-anaerobic infection pharmaceutical preparations, which are suitable for clinical uses.

The invention discloses an antibacterial peptide P104 and lyase LysP53 with the broad-spectrum splitting activity, and application of the antibacterial peptide P104 and the lyase LysP53. The amino acid sequence of the antibacterial peptide P104 is as shown in SEQ ID NO.1, and the gene sequence of the antibacterial peptide P104 is as shown in SEQ ID NO.3; the amino acid sequence of the lyase LysP53 is as shown in SEQ ID NO.2, and the gene sequence of the lyase LysP53 is as shown in SEQ ID NO.4; the antibacterial peptide P104 and the lyase LysP53 have a relatively good splitting effect on acinetobacter baumannii, pseudomonas aeruginosa, klebsiella pneumoniae and escherichia coli in vitro, and can be used for splitting gram-negative bacteria in a broad-spectrum manner; meanwhile, the lyase LysP53 can be subjected to soluble expression in escherichia coli, and the enzyme activity is high, and thus, the antibacterial peptide P104 and the lyase LysP53 have relatively good application prospects in research and development of anti-infection drugs.

The present invention relates to the technical field of medicines and discloses dryopteris fragrans phloroglucinol derivatives, a separation and preparation method for isomers thereof and an application thereof Phloroglucinol compounds are separated and prepared from dryopteris fragrans(L.)Schott, which belongs to dryopteridaceae dryopteris plants, for the first time, and 4 pairs of isomers are discovered, wherein the 4 pairs of isomeric compounds have relatively strong effect of resisting skin superficial fungi. According to the in-vitro bacteriostatic experiment, the compounds provided by the present invention have good bacteriostatic effect on two skin pathogenic fungi, namely trichophyton rubrum and microsporum gypseum, and have characteristics of being low in side effect and being not liable to become resistant to the drug, and the like, thereby providing a novel natural compound for the treatment of skin superficial fungi infection and providing powerful technical support for preparing anti skin superficial fungi infection drugs or pharmaceutical compositions.

The invention discloses application of 2,6-bis(2-benzimidazolyl) pyridine in preparation of a carbapenem-resistant pseudomonas aeruginosa infection drug. Through circular dichroism, fluorescent real-time quantitative PCR and other methods, it is found that 2, 6-bis (2-benzimidazolyl) pyridine can form a G-quadruplex structure with a core sequence of a MexA gene in pseudomonas aeruginosa, thereby inhibiting expression of the MexA gene. A susceptibility testing verifies that 2, 6-bis (2-benzimidazolyl) pyridine can reduce the drug resistance of carbapenem-resistant pseudomonas aeruginosa to meropenem. When the usage amount of the 2, 6-bis (2-benzimidazolyl) pyridine is 5 <mu>M, the minimum inhibitory concentration of the carbapenem-resistant pseudomonas aeruginosa strain can be reduced to 2<mu> g/ml, and the effect of treating carbapenem-resistant pseudomonas aeruginosa infection by using meropenem is achieved.

The present invention discloses an antisense oligonucleotide sequence for inhibiting growth of multidrug resistant Acinetobacter baumannii, and an application thereof, and belongs to the field of novel antibacterial preparation research and development. According to the invention, the computer-assisted design and oligonucleotide dot blot hybridization combined technology is adopted to screen the antisense oligonucleotide adopting coding gene gyrA of the multidrug resistant Acinetobacter baumannii topoismerase IIA subunit as target gene so as to inhibit growth of multidrug resistant Acinetobacter baumannii; the antisense oligonucleotide sequence has significant multidrug resistant Acinetobacter baumannii growth inhibition activity at a low concentration, and can present rapid and efficient bactericidal activity (ie., cause death of multidrug resistant Acinetobacter baumannii) when the concentration is increased; and the designed antisense nucleic acid has characteristics of strong inhibition activity and high specificity, is suitable for treatment of multidrug resistant Acinetobacter baumannii infections, and can be potentially developed into the anti-multidrug resistant Acinetobacter baumannii infection drug.

The invention provides a Cq-Ns1abp gene for inhibiting WSSV infection and application of protein thereof in resistance of virus activity and relates to white spot syndrome viruses. The Cq-Ns1abp geneis ligated into a prokaryotic expression vector pMal-C2x to construct an anti-WSSV infection regulatory factor pMal-C2x-Cq-Ns1abp recombinant expression vector of chrtax quadricarinatus. A Cq-Ns1abp gene product contains an N-end BTB structural domain and C-end Kelch structural domain protein and full-length protein; obtained recombinant expression vector transformants are introduced into host cells respectively for inducing expression to obtain expressed products, and rCq-Ns1abp recombinant protein with higher purity is obtained through affinity chromatography. Since Cq-Ns1abp has an inhibitory effect on WSSV infection, Cq-Ns1abp has an important effect on antiviral immunity of shrimps. Therefore, an anti-WSSV infection regulatory factor of chrtax quadricarinatus is applied in preparationof antiviral infection drugs and animal disease-resistant feed additives.

The invention relates to the technical field of medical catheters, in particular to a hemodialysis medical catheter for dialysis and a preparation method of the hemodialysis medical catheter. The medical catheter comprises a catheter body and an antibacterial coating coated on the surface of the catheter body, wherein the catheter body is prepared from polyvinyl chloride plastic, modified filter residues, magnesium carbonate, silicon dioxide and ethidene diamine; and the antibacterial coating is prepared from copper powder and an anti-infection drug. Mulberry bark is used as a raw material, is treated by a propyl alcohol solution, and cooperates with the magnesium carbonate, the silicon dioxide and the ethidene diamine, so that the antibacterial performance of the medical catheter is improved. The antibacterial coating is prepared from anti-infection medicine raw materials and sprayed to the surface of the medical catheter, and the antibacterial performance of the medical catheter can be further improved.

The invention relates to cervinomycin B1, B2, B3 and B4 and a production method and application thereof. Chemical structures of the cervinomycin B1, B2, B3 and B4 are as shown in formulae of (1), (2),(3) and (4). The production method comprises the following steps: through fermenting and culturing streptomycete of which a preservation number is CGMCC NO. 16425, harvesting a fermentation culture object, and performing extracting, separating and purifying to obtain the cervinomycin B1-B4 components. The cervinomycin B1-B4 components are expected as a lead compound for researching and developingan anti-bacterial infection drug.

The invention relates to the field of biological engineering, in particular to an Escherichia coli lyase as well as a preparation method and application thereof as an anti-infection drug. The Escherichia coli lyase is characterized in that an amino acid sequence is Seq ID NO.2. Enzymic preparations capable of effectively killing Escherichia coli are developed by utilizing a bioengineering technology. The preparations can be used independently or can be compounded to use, can specifically deactivate multiple Escherichia coli, and a safe and nontoxic enzyme preparation source with no side effect can be provided for controlling the Escherichia coli in garget at present.

The invention relates to the field of pharmacy, in particular to application of antimicrobial peptides in anti-mycobacteria infection drugs. According to the application, starting with antimicrobial peptides, a series of antimicrobial peptides aiming at mycobacteria with special structures and unusual action modes are researched and developed, the antimicrobial peptides kill bacteria through a membrane destruction mechanism, and the bacteria do not generate drug resistance. The antimicrobial peptides, as main potential medicament for treating tuberculosis, fill the gap of no new anti-tuberculosis drugs in China for a long time. Therefore, the antimicrobial peptides provided by the application can be used for preparing effective drugs aiming at the mycobacteria, are expected to be the anti-mycobacteria infection potential drugs, and are the main potential medicament for treating the tuberculosis.

The invention discloses application of S-methylisothiourea sulfate in preparation of anti-influenza virus and escherichia coli co-infection drugs. Experiments prove that at the cellular level, the compound S-methylisothiourea sulfate can significantly inhibit proliferation of escherichia coli under the condition of mixed infection; at the animal level, after S-methylisothiourea sulfate (20mg/kg/mouse) is dropped into a mouse in a nasal dropping mode, the resistance of the mouse to H9N2 subtype influenza virus and escherichia coli mixed infection is enhanced, the survival rate of the mouse infected with H9N2 subtype influenza virus and escherichia coli is increased compared with that of a mouse infected with H9N2 subtype influenza virus and escherichia coli without dropping S-methylisothiourea sulfate, and the carrying capacity of influenza virus and escherichia coli in the lung is obviously reduced. The compound is effectively applied to resisting influenza virus and escherichia coli mixed infection, can serve as a new candidate drug for resisting influenza virus and escherichia coli mixed infection, and provides more choices for treatment of influenza virus and escherichia coli mixed infection clinically.

The invention provides an antibacterial peptide composition. The amino acid sequence of the antibacterial peptide is KWKSFLKTFaAbKTVLHTALKAISS, and substitution sites of a and b are selected from any amino acids as follows: L-leucine, D-leucine, L-valine, D-valine, L-alanine, D-alanine, glycine, L-serine, D-serine, L-lysine and D-lysine. The composition comprises at least one stabilizer, antibacterial peptide and a buffer system (preferably disodium hydrogen phosphate and citric acid), and the pH value of the composition is 3.5-5.5. The antibacterial peptide composition is a broad-spectrum anti-infection drug for local external use, is suitable for various primary skin infections caused by pathogenic bacteria, especially drug-resistant bacteria, and secondary skin infections such as eczema combined infection and ulcer combined infection, including stubborn infectious diseases such as diabetic foot, burn wound infection and bedsore infection, and has a wide application prospect.

The invention belongs to the technical field of biological medicine, and particularly relates to application of adenosine or adenosine monophosphate in preparation of anti-infective drugs. The invention relates to a preparation method of the medicine. Adenosine or adenosine monophosphate can significantly improve the effect of clinical escherichia coli, aeromonas hydrophila, vibrio including vibrio alginolyticus and vibrio parahaemolyticus, streptococcus pyogenes, pseudomonas aeruginosa, bacillus faecium, streptococcus iniae, acinetobacter baumannii, klebsiella pneumoniae and other bacteria on the effects of cefoperazone sulbactam, ceftazidime, ceftriaxone sodium, ceftazidime, ceftriaxone sodium, ceftazidime, ceftriaxone sodium, ceftazidime sodium and the like. The sensitivity of antibiotics such as cefoperazone, meropenem, imipenem, ciprofloxacin, ampenem, moxifloxacin, levofloxacin, gentamicin, amikacin, kanamycin and the like is improved, the compound can be used together with the antibiotics to serve as an anti-infection drug, bacteria are killed under the condition of low-concentration antibiotics, and a good anti-infection effect is achieved; meanwhile, the generation of bacterial drug resistance is reduced.

The invention discloses a method for determining anti-infection drugs in cosmetics, and relates to the technical field of cosmetic component determination. The problems that the screening range is narrow and the detection method is inaccurate are solved. The method specifically comprises the following steps: preparing a determination material and a determination instrument, preparing a determination standard solution, preparing and determining three blank matrix solutions, determining instrument determination reference conditions including a chromatographic condition and a mass spectrum condition, carrying out parameter verification by adopting a QC sample, screening anti-infection drugs in cosmetics, calculating and establishing a database. The time-of-flight scanning mass spectrometry is adopted, so that the method has high selectivity, accuracy and precision, and has important practical significance for guaranteeing the quality safety of cosmetics and protecting the health of consumers.